Evidence map›Paper›PMID 22987089›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2012

L-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial.

Ricardo A Cruciani, Jenny J Zhang, Judith Manola, David Cella, Bilal Ansari, Michael J Fisch

2 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase IIIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 44 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 8 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00091169 phase3completednot on this map

Phase III Randomized Placebo-Controlled Trial to Determine Efficacy of Levocarnitine for Fatigue in Patients With Cancer

TypeinterventionalSponsorECOG-ACRIN Cancer Research GroupRan2005 to 2011Enrolled376ConditionsFatigue, Unspecified Adult Solid Tumor, Protocol SpecificArmslevocarnitine, placebo
NCT06233890 unknown statusnot on this mapstarted 2023, after this paper: background citation

The Analysis of Fatigue on Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia

TypeobservationalSponsorImperial College Healthcare NHS TrustRan2023 to 2026Enrolled50ConditionsChronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase, Fatigue, Sleep DisturbanceArmsMotion watch
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 8 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Management of Fatigue in Adult Survivors of Cancer: ASCO-Society for Integrative Oncology Guideline Update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Guideline
  3. Pooled it
  4. Pooled it
  5. The efficacy of placebo for the treatment of cancer-related fatigue: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Pharmacological treatments for fatigue associated with palliative care.The Cochrane database of systematic reviews · 2015
    Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Can levocarnitine supplementation improve fatigue caused by sunitinib as a treatment for renal cell carcinoma? A single-center prospective pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019
    Trial
  13. Trial
  14. Trial
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ricardo A CrucianiDepartment of Pain Medicine and Palliative Care, Beth Israel Medical Center, New York, NY 10003, USA. rcruciani@chpnet.org
Jenny J Zhang
Judith Manola
David Cella
Bilal Ansari
Michael J Fisch
Dana-Farber Cancer Institute · US

Funding

Foreign Accrual - ECOGU10CA037403 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI COMIS, ROBERT L · 1985 to 2014
$34.6M
PROVIDE STATISTICAL SERVICESU10CA023318 · NCI · DANA-FARBER CANCER INSTITUTE · PI GRAY, ROBERT J · 1985 to 2013
$33.4M
ECOG Specimen BankingU24CA114737 · NCI · FRONTIER SCI &TECHNOLOGY RSCH FDN, INC · PI COMIS, ROBERT L · 2005 to 2014
$9.3M
NCI NIH HHS CA-23318NCI NIH HHS U10 CA023318NCI NIH HHS U10 CA037403NCI NIH HHS U24 CA114737
6 · The paper itself

Abstract

purposeL-carnitine, a popular complementary and alternative medicine product, is used by patients with cancer for the treatment of fatigue, the most commonly reported symptom in this patient population. The purpose of this study was to determine the efficacy of L-carnitine supplementation as a treatment for fatigue in patients with cancer. PATIENTS AND

methodsIn this double-blind, placebo-controlled trial, patients with invasive malignancies and fatigue were randomly assigned to either 2 g/d of L-carnitine oral supplementation or matching placebo. The primary end point was the change in average daily fatigue from baseline to week 4 using the Brief Fatigue Inventory (BFI).

resultsThree hundred seventy-six patients were randomly assigned to treatment with L-carnitine supplementation or placebo. L-carnitine supplementation resulted in significant carnitine plasma level increase by week 4. The primary outcome, fatigue, measured using the BFI, improved in both arms compared with baseline (L-carnitine: -0.96, 95% CI, -1.32 to -0.60; placebo: -1.11, 95% CI -1.44 to -0.78). There were no statistically significant differences between arms (P = .57). Secondary outcomes, including fatigue measured by the Functional Assessment of Chronic Illness Therapy-Fatigue instrument, depression, and pain, did not show significant difference between arms. A separate analysis of patients who were carnitine-deficient at baseline did not show statistically significant improvement in fatigue or other outcomes after L-carnitine supplementation.

conclusionFour weeks of 2 g of L-carnitine supplementation did not improve fatigue in patients with invasive malignancies and good performance status.

Indexed as

CarnitineComplementary TherapiesDietary SupplementsDouble-Blind MethodFatigueFemaleHumansMaleNeoplasmsTreatment OutcomeCarnitine

Identifiers

PMID22987089
PMCPMC3478577
OpenAlexW1964151928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.